PharmaShots

JUNE 9, 2023

Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies Date: June 09, 2023 | Tags: Quell Therapeutics, AstraZeneca, Engineered Treg Cell Therapies, Type 1 Diabetes, Inflammatory Bowel Disease, Biotech, Treg cell engineering modules Astellas and the (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 24, 2023

Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive

FDA 40

FDA Vaccines 40

PharmaShots

APRIL 28, 2023

Difficile Infection Date: Apr 27, 2023 | Tags: Seres Therapeutics, Nestlé Health Science, Vowst, C.

FDA 56

FDA 56

PharmaShots

JUNE 2, 2023

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734 Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic (..)

FDA 40

FDA 40

PharmaShots

MAY 19, 2023

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Medical Schools 40

Medical Schools FDA Immunization Vaccines 40

Pharmaceutical Technology

MAY 19, 2023

DMTs for MS have a high price tag, particularly in the US. According to GlobalData’s recent Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update report, which identified 19 DMTs marketed for MS in the US, the average annual cost of therapy increased by 9% between 2020 and 2022.

98

98

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

Pharmaceutical Technology

SEPTEMBER 30, 2022

Prior to bluebird's approvals, there were only two FDA-approved gene therapies for inherited conditions on the market. Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye.

FDA 115

FDA Insurance 115

STAT

OCTOBER 6, 2022

And this is especially true for us, since we hit the proverbial pause button yesterday to observe ancient rituals. Please feel free to join us. million tag as cost effective for a Bluebird Bio drug called Zynteglo for the blood disorder beta thalassemia, Arbuckle said in an interview. Our choice today is Jack Daniels.

88

88

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

FDA 109

FDA 109

STAT

AUGUST 2, 2023

The middle of the week is upon us. Meanwhile, do keep us in mind if you hear anything interesting. Medicare and Medicaid patients will make up 92% of the market for the drug, called Leqembi. Besides the $26,500 annual price tag, treatment could cost U.S. Have heart, though.

Insurance Coverage 87

Insurance Coverage Insurance 87

Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. The second highest contributing market is APAC, generating 33.2%

52

52

pharmaphorum

JULY 23, 2019

Customer journeys in pharma are changing, with important implications for the marketing supply chain. How can pharmaceutical marketers capitalise on this trend and free up budget to invest in additional marketing channels? Overview Join our live webinar taking place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Access to oncology medicines varies across countries, and their cost against safety/efficacy is generally perceived as being low, such as in the US. Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s

FDA 105

FDA 105

Pharmaceutical Technology

JANUARY 17, 2023

On January 12, Versanis Bio announced that enrollment had begun for its Phase IIb trial, BELIEVE (NCT05616013), which aims to study bimagrumab’s (BYM-338) efficacy and safety in the US, among other locations. Mounjaro is anticipated to launch in the US later this year or by early 2024. was observed in the study.

Hospitals 52

Hospitals 52

Roots Analysis

MARCH 1, 2024

Such disadvantages of overt security technologies can be overcome using certain covert security features. Track & Trace technologies constitute a separate segment in the anti-counterfeiting technologies market. Some of the countries include the US, the EU, China, India, Japan, Korea, Brazil, Turkey and Argentina.

Packaging 52

Packaging Labelling 52

pharmaphorum

SEPTEMBER 15, 2020

As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. This is reinforced by web-focused marketing strategies that give them a highly-targeted approach when it comes to marketing execution.”. Be more agile .

Communication 120

Communication Documentation Labelling Vaccines 120

Pharmaceutical Technology

DECEMBER 5, 2022

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. In the US, the world’s largest pharmaceutical market, most states have legalized cannabinoids for medical use.

Controlled Substances 98

Controlled Substances Compounding Immunization 98

Pharmaceutical Technology

JULY 14, 2022

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Hospitals 59

pharmaphorum

AUGUST 17, 2020

N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Personalising marketing content. Engagement channels. Joanna Carlish.

Communication 93

Communication Insurance Packaging Pharmaceutical Companies 93

DiversifyRx

JUNE 23, 2023

Email marketing is one of the most cost-effective ways to increase pharmacy growth, but which CRM should you use? I used to email every patient manually because I had so few. A popular one I have heard about is Mailchimp, but I also have heard it is challenging to use. Your CRM is the engine of your email marketing.

52

52

Pharmaceutical Technology

JUNE 29, 2022

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

JUNE 12, 2022

The FDA still has to deliver its own verdict on the applications, and doesn’t always follow its advisors’ lead, but with two unanimous decisions bluebird looks set up for its first approvals in the US. Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8

FDA 57

FDA 57

pharmaphorum

JANUARY 9, 2023

Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its orally-administered therapy Evrysdi (risdiplam) in 2020. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1

117

117

Pharmaceutical Technology

NOVEMBER 9, 2022

In the EU however, two years later, the European Commission awarded a conditional marketing authorisation for Roctavian. The European Commission withdrew the marketing authorisation of Zynteglo, at the request of bluebird bio, in March 2022. million price tag. million ($1.5 million ($1.8 million at the time).

FDA 111

FDA 111

pharmaphorum

AUGUST 21, 2022

Auvelity isn’t the first NMDA-targeting antidepressant to reach the market. The biotech hasn’t revealed much information about the reasons for the delay in getting approval, but said in an SEC filing in June this year that it had agreed to “post-marketing commitments” proposed by the FDA, without going into details.

FDA 98

FDA Labelling 98

pharmaphorum

NOVEMBER 19, 2020

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

FDA 62

FDA Labelling 62

Pharmaceutical Technology

MAY 2, 2023

There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications. Marketed bispecific antibodies are largely bispecific T-cell engagers (BiTEs), which work by directing T-cells to antigen-expressing tumour cells. Cost-related unmet needs also scored highly.

Immunization 52

Immunization Vaccines 52

pharmaphorum

APRIL 14, 2022

US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed $2.1 million price tag.

FDA 62

FDA 62

ISPE

DECEMBER 1, 2022

Winner of the ISPE Italy Affiliate’s Women in Pharma® Graziella Molinari Award in 2021, thanks to her project for the inclusion of #smart tags in a site production in order to improve not only efficiency, but also quality and compliance in a 4.0 Micaela Prati. perspective. .

98

98

Pharmaceutical Technology

FEBRUARY 22, 2023

Amgen could be the winner of a high-stakes patent spat with Sanofi as tensions run high weeks before the March 27 US Supreme Court hearing. Both drugs come with a high price tag. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US.

FDA 104

FDA 104

pharmaphorum

JUNE 2, 2022

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. This is why the action by the US in 1983 and subsequently the European Commission Regulation No. The price is right. Raising questions.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 8, 2021

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” — Dr. Patrizia Cavazzoni (@FDACDERDirector) June 7, 2021.

FDA 98

FDA Labelling 98

pharmaphorum

JANUARY 11, 2021

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market. million price tag. Zynteglo is already in beta-thalassemia in Europe, where the company will seek to expand access despite its hefty $1.8

FDA 59

FDA 59

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52

FDA 52

pharmaphorum

JULY 25, 2022

J&J filed for approval of the bispecific in the US in December based on the results of the phase 1b MajesTEC-1 study in myeloma patients who had been treated with a median of five lines of prior therapy. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

FDA 52

FDA 52

pharmaphorum

NOVEMBER 24, 2022

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its take-up.

Labelling 52

Labelling Hospitals 52